| Objective To discuss the efficacy of ibandronate sodium combined with Alfacalcidol on osteoporosis in patients with endocrine therapy after breast cancer surgery. Methods Ninety osteoporotic patients with endocrine therapy after breast cancer surgery were randomly divided into control group and study group, with 45 cases in each group. Patients in the control group received oral Alfacalcidol 0.5μg per time, 2 times per day, on the basis of conventional treatment for 1 years. Patients in the study group received intravenous ibandronate sodium, 2mg at the first dose, 3mg every 3 months thereafter, on the basis of the control group, for 1 year. The efficacy, bone mineral density (BMD), and adverse reaction were recorded and compared. Results (1) The total effective rate of was 73.33% (33/45) in the control group, and 91.11% (41/45) in the study group. The difference between the two groups was statistically significant (P<0.05). (2) After treatment, BMD of the lumbar, femoral neck and Ward’s triangle areas in both groups improved significantly, compared with those before treatment, and the difference was statistically significant (P<0.05). The improvement of BMD in the study group was better than that in the control group, and the difference was statistically significant (P<0.05). (3) During the treatment, there were 7 cases of adverse reaction in the control group, and the incidence rate was 15.6% (7/45). There were 12 cases of adverse reaction in the study group, and the incidence rate was 26.7% (12/45). The difference between the two groups was not statistically significant (P<0.05). Conclusion Ibandronate sodium combined with Alfacalcidol enhances clinical efficacy for the treatment of the osteoporotic patients with endocrine therapy after breast cancer surgery. It also relieves the the clinical symptoms and improves BMD, with no obvious adverse reaction. It is worthy of further clinical application. |